Memantine is FDA-approved for moderate to severe Alzheimer’s disease. It is not approved for mild dementia or mild cognitive impairment, and clinical trials have not shown meaningful benefits at those earlier stages. If you or a loved one has been prescribed memantine, it typically means the disease has progressed beyond the mild phase.
Why Moderate to Severe, Not Mild
The FDA approved memantine in 2003 specifically for moderate to severe Alzheimer’s dementia. In 2004, the manufacturer applied to expand that approval to include mild Alzheimer’s, but the FDA issued a non-approvable letter in 2005, requiring a confirmatory study that never materialized. The drug has never been formally approved for early-stage disease.
The clinical evidence backs that decision. Two six-month trials in patients with mild to moderate Alzheimer’s produced mixed results. One U.S. study of 403 patients showed modest benefits on cognitive and global outcome scales. A European trial of 470 patients showed benefits only at interim checkpoints and fell short of statistical significance by the end. Meta-analyses since then have reached conflicting conclusions, with one prominent review in 2011 finding a lack of evidence for efficacy in mild Alzheimer’s. The American Academy of Neurology states plainly that memantine has not demonstrated benefits in patients with mild Alzheimer’s or mild cognitive impairment.
Despite all this, memantine is frequently prescribed off-label at the mild stage. Whether it provides any real clinical value there remains controversial.
How Memantine Works
Memantine works differently from the other main class of Alzheimer’s medications (cholinesterase inhibitors like donepezil). It targets a specific type of receptor in the brain that responds to glutamate, one of the brain’s primary chemical messengers. In a healthy brain, glutamate helps with learning and memory. In Alzheimer’s, damaged cells can release too much glutamate, which overstimulates nearby neurons and accelerates their death.
Memantine acts as a selective blocker. It sits in the receptor’s channel and reduces the constant low-level noise of excess glutamate, while still allowing the stronger, purposeful signals involved in forming memories to pass through. Think of it as a filter: it dampens the harmful background chatter without silencing the signals that matter. This is a symptomatic treatment. It does not slow or stop the underlying neurodegeneration of Alzheimer’s disease.
What Memantine Can and Cannot Do
In moderate to severe Alzheimer’s, memantine can temporarily improve or stabilize thinking ability, behavior, and the capacity to handle everyday tasks. A study published in Neurology found that patients on memantine combined with a cholinesterase inhibitor experienced less functional decline than those on a cholinesterase inhibitor alone. At study’s end, 9.6% of patients on placebo had a major drop in daily functioning compared to 4.9% of those on memantine.
These are real but modest effects. Memantine will not restore lost cognitive function or reverse the course of the disease. And the benefits of memantine as a standalone treatment tend to fade by about 12 months. For this reason, it appears to offer the most value when added to an existing cholinesterase inhibitor rather than used on its own.
Combination Therapy With Donepezil
A combination pill containing both memantine and donepezil is available for moderate to severe Alzheimer’s. This pairing targets two different mechanisms: donepezil boosts levels of a chemical messenger involved in memory, while memantine filters out excess glutamate signaling. The combination may improve thinking, behavior, and functional ability more than either drug alone, though it will not cure or halt the disease.
Many patients start on a cholinesterase inhibitor during the mild stage and then add memantine as the disease progresses into moderate territory. This step-up approach is one of the most common treatment paths in clinical practice.
How Dosing Works
Memantine comes in two forms: an immediate-release tablet taken twice daily and an extended-release capsule taken once daily. Both are started at a low dose and gradually increased over several weeks.
The extended-release version starts at 7 mg once daily and increases in 7 mg steps, with at least one week between each increase, up to a target of 28 mg once daily. The immediate-release version follows a similar stepwise approach up to 10 mg twice daily. This gradual titration helps minimize side effects. Patients with significant kidney problems typically stay at a lower maximum dose.
When Memantine Is Stopped
There is growing clinical consensus that memantine, along with cholinesterase inhibitors, should be “deprescribed” for patients who have reached the advanced or end stage of Alzheimer’s disease. At that point, the symptomatic benefits are no longer clinically meaningful, and continuing medication adds pill burden without clear value. This decision is typically made on a case-by-case basis as the disease progresses beyond the moderate-to-severe window where evidence supports its use.